...jeffrey krasner is president of emerging biocommunications, which consults to early- and mid-stage life science companies...
schneider said that he is "not aware of any relevant risk of the drug" and that his team has "not observed side effects in thousands of treated animals.".
suven life sciences' pashamylaram facility successfully completes usfda inspection